5 mg of lyophilized Imiquimod Vaccine grade adjuvant
10 ml sterile endotoxin-free physiological water (NaCl 0.9%)
Storage and Stability
Imiquimod is shipped at room temperature and should be stored at -20°C. Lyophilized product is stable 1 year when properly stored.
- Upon resuspension, prepare aliquots of Imiquimod and store at -20°C. Resuspended product is stable 6 months when properly stored. Avoid repeated freeze-thaw cycles.
Imiquimod, an imidazoquinoline amine analogue to guanosine, is an immune response modifier with potent antiviral and antitumor activities. Imiquimod is approved for the topical treatment of genital warts, basal cell carcinoma, and bladder cancer. Imiquimod exerts its immune-modulating activity by inducing the production of pro-inflammatory cytokines, such as IFN-a and IL-12, leading to the activation of both innate and acquired immunity. This activity of Imiquimod is in part due to its capacity to bind to and stimulate Toll-like receptor (TLR)-7, suggesting a potential role of Imiquimod to act as an adjuvant. Preclinical studies in mice have shown the effectiveness of Imiquimod in inducing immune responses to immunization using various vaccination strategies. Imiquimod has been shown to increase both antibody and cell-mediated immune responsiveness induced by a DNA vaccine. In a genetically engineered mouse model, a DNA vaccine encoding HER2/neu adjuvanted with Imiquimod was reported to significantly delay the development of spontaneous mammary tumors. This antitumor effect was accompanied by a significant increase in Ag-specific antibody (Ab) production and in CTL activity, and a switch from IgG1 to IgG2a Ab isotype, suggesting a Th1 polarization of the immune response.
Preparation of Sterile Stock Solution (1 mg/ml)
Add 5 ml endotoxin-free physiological water to the 5 mg Imiquimod vial to obtain a solution at 1 mg/ml.
- Mix the solution by pipetting up and down.
Formula: C14H16N4, HCl
Molecular weight: 276.8
Solubility: 1 mg/ml in physiological water